Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety

BACKGROUND: Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is commonly used to prevent febrile neutropenia (FN), a potentially life-threatening complication, following myelosuppressive chemotherapy. The FDA label for pegfilgrastim specifies that it should not be administ...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahtani, Reshma, Crawford, Jeffrey, Flannery, Sinéad M., Lawrence, Tatiana, Schenfeld, Jennifer, Gawade, Prasad L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157684/
https://www.ncbi.nlm.nih.gov/pubmed/34044798
http://dx.doi.org/10.1186/s12885-021-08258-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157684/
https://www.ncbi.nlm.nih.gov/pubmed/34044798
http://dx.doi.org/10.1186/s12885-021-08258-w

Ejemplares similares